Study Published in the Journal of Medicinal Chemistry Demonstrates the Power of Machine Learning to Unlock New Chemistry and Biology to Treat Disease
WALTHAM, Mass. – June 11, 2020 – X-Chem, Inc., the leader in DNA-encoded small molecule library screening, and ZebiAI Therapeutics, a drug discovery company unlocking new disease targets, today announced the publication of a large prospective study to evaluate the power of machine learning (ML) to accelerate and improve the drug discovery process. The study, published in the Journal of Medicinal Chemistry, titled “Machine Learning on DNA-encoded Libraries: A New Paradigm for Hit-finding,” was conducted in collaboration with Google Accelerated Science (GAS), who developed the highly predictive ML algorithms.
Going Beyond Hit ID With Machine Learning & Del: The Prediction of Building Block Reactivity
Since X-Chem and Google’s seminal collaboration applying machine learning (ML) to DNA-encoded chemical library (DEL) screening output, ML has taken...
Privacy Policy
English French Hungarian Cookie Settings Your privacy is important to X-Chem and its affiliates (hereinafter “we” and/or “us” and/or “X-Chem”) and we...
Full-length in meso structure and mechanism of rat kynurenine 3-monooxygenase inhibition
Otsuka and X‑Chem Enter into a Drug Discovery Research and License Collaboration
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and X-Chem, Inc. (X-Chem) announce that they have signed a collaborative research agreement to advance the discovery process for new Otsuka drug compounds.
X‑Chem and Ono Enter into Multi-Target Drug Discovery Collaboration
WALTHAM, Mass. – March 21, 2017 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, today announced a partnership with Ono Pharmaceutical Co., Ltd. (Ono). Under the terms of the agreement X-Chem will apply its proprietary DEXTM libraries, which contain over 120 billion small molecules, toward the discovery of new drug leads against multiple promising, high-impact oncology targets. Ono will have the option to license identified lead compounds and will be responsible for further development and commercialization of any resulting programs. X-Chem receives an upfront payment, research and licensing fees, and is eligible for additional payments linked to the successful achievement of pre-clinical and clinical development markers, as well as regulatory milestones, in addition to royalties on sales of products originating from the collaboration. No further financial terms will be disclosed.
ZebiAI Therapeutics, Inc. and X‑Chem Enter into Strategic Agreement to Enable Validation of Novel Therapeutic Targets and Acceleration of Drug Candidate Discovery
New venture capital-backed artificial intelligence company to utilize X-Chem’s leading DNA encoded library screening service WALTHAM, Mass. – ZebiAI Therapeutics, Inc. and X-Chem, Inc., both of Waltham, MA, and privately held companies, today announced a multiyear service and license agreement. The agreement provides ZebiAI access to X-Chem’s proprietary DNA Encoded Library technology (DEX™) for the discovery of novel small molecules to support ZebiAI’s Chemome Initiative – the identification of probe molecules for novel targets – and drug candidate identification to build upon discoveries from the Chemome effort. The collaboration additionally marks the establishment of ZebiAI Therapeutics alongside a funding round led by Anterra Capital.
X‑Chem and Vertex Enter into Multi-Target Genetic Disease Collaboration
– Agreement will enable discovery of small-molecule leads against validated targets for severe, genetic diseases– X-Chem to receive upfront payment...